IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)
Participants required: 24
Investigator responsible(s): A. Stathis, D. Rossi, E. Zucca
Objective(s): The primary objective of the IELSG49 trial is to determine the efficacy of tafasitamab in combination with acalabrutinib in patients with relapsed or refractory MZL.

Home | Go to Studies